Search clinical trials for: Acalabrutinib Treatment A

Total 21036 results

AstraZeneca
Acerta Pharma, LLC

Completed

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Pharmacokinetics | Bioavailability

United States
AstraZeneca
Parexel

Completed

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

COVID-19 | Mantle Cell Lymphoma

Germany
AstraZeneca

Completed

Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

Bioequivalence

United States
Acerta Pharma BV
National Institutes of Health (NIH)

Active, not recruiting

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
AstraZeneca
Acerta Pharma BV

Completed

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI)

COVID-19

Italy, Turkey, Brazil, Japan, South Africa, Germany, Poland, Russian Federation, India, Peru, France, Argentina, Chile, Mexico
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Mantle Cell Lymphoma (MCL)

United States, Poland, Italy
Pfizer

Completed

A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804

Healthy Volunteers

Belgium
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
Rennes University Hospital

Recruiting

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release (DIPLOID)

Pharmacokinetics

France
Pfizer

Completed

Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Healthy

Singapore
Pfizer

Completed

A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550

Arthritis, Rheumatoid

Singapore
Pfizer

Completed

A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers (B0871003)

Pharmacokinetics

Singapore
Hospices Civils de Lyon

Completed

Rehabilitation For Acquired Visual Field Defects: Development Of A Bottom-Up Approach (VISIOTRAIN)

Acquired Visual Field Defects

France
Pfizer

Completed

Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532

Healthy

United States
Novartis Pharmaceuticals

Completed

Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718

Coronary Artery Disease

United Kingdom
Pfizer

Completed

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers. (B0871002)

Healthy

Singapore
Acerta Pharma BV

Active, not recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Chronic Lymphocytic Leukemia

United States, United Kingdom, Belgium, Spain, Israel, France
Altamira Medica Ltd.

Completed

Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Rhinitis, Allergic | Perennial Allergic Rhinitis

Canada
AstraZeneca

Completed

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma

India
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Pfizer

Completed

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

Asthma

Singapore
JW Pharmaceutical

Completed

To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers

Healthy

Korea, Republic of
Alexion Pharmaceuticals
Parexel

Completed

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Healthy Adult Participants

United States
Chiesi Farmaceutici S.p.A.

Completed

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Terminated

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma (PERSEA)

Asthma; Eosinophilic

Bulgaria
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
Kartos Therapeutics, Inc.

Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Belgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Waldenström Macroglobulinemia (WM)

Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
PETHEMA Foundation

Active, not recruiting

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia- Binet Staging System

Spain
Pfizer

Completed

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Healthy

Singapore
Pfizer

Completed

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

Pharmacokinetics

Singapore
Celltrion

Completed

A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers

Health, Subjective

Korea, Republic of
Medical University of Vienna
Pharmig - Gesundheitsziele aus dem Rahmen-Pharmavertrag

Active, not recruiting

Maudsley Model of Anorexia Nervosa Treatment for Adolescents and Young Adults (MANTR-a)

Anorexia Nervosa | Anorexia

Austria
AstraZeneca

Completed

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Germany
Baylor College of Medicine

Not yet recruiting

CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) (CASEY)

Lymphoma | Leukemia, Myeloid, Acute | Leukemia, T-Cell | Leukemia, B-cell

United States
Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Healthy

United States
Reckitt Benckiser Healthcare (UK) Limited
Intertek

Completed

Evaluation of the Performance of a Fungal Nail Treatment on the Visual Signs of Onychomycosis

Onychomycosis of Toenails

United Kingdom
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

CLL/SLL

Netherlands, Belgium, Denmark
Biogen

Completed

New Formulation and Food Effect Study of BIIB074

Trigeminal Neuralgia (TN) | Other Neuropathic Pain

United States
Pfizer

Completed

A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Healthy

Singapore
Taejoon Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy

Bowel Preparation

Korea, Republic of
Trent Stellingwerff
University of British Columbia; Mitacs

Recruiting

Relative Energy Deficiency in Sport Multicenter Study

Nutrition Disorders | Health, Subjective | Cardiovascular Abnormalities | Bone Loss | Athletic Injuries | Mental Health Wellness 1 | Eating Disorders | Hormone Disturbance | Sleep Hygiene | Weight Change, Body | Bone Fracture | Exercise-related Amenorrhea

Canada
Bayer

Completed

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Pfizer

Completed

A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects

Rheumatoid Arthritis

Singapore
University of Essex
Chartered Society of Physiotherapy

Recruiting

Managing Achilles Pain II (MAP II)

Achilles Tendinopathy

United Kingdom
Mayur Narkhede
ADC Therapeutics S.A.

Recruiting

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
Daiichi Sankyo, Inc.

Completed

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

Food Effects on Pharmacokinetics

United States
Medical University of South Carolina
National Institute on Drug Abuse (NIDA)

Completed

Research on Outpatient Adolescent Treatment for Comorbid Substance Use and Internalizing Disorders

Substance-Related Disorders | Depressive Disorder | Anxiety Disorder

United States

3

Subscribe